PCN14 A Pharmacoeconomic Appraisal of Cabazitaxel Versus Abiraterone for the Second-Line Treatment of Patients with Metastatic Hormone-Refractory Prostate Cancer (MHRPC) Progressing After the Treatment with Docetaxel: a Systematic Review

Bektur, C.Nurgozhin, T.2017-12-132017-12-132014-05-0110983015https://www.sciencedirect.com/science/article/pii/S1098301514004604http://nur.nu.edu.kz/handle/123456789/2871PCN14 A Pharmacoeconomic Appraisal of Cabazitaxel Versus Abiraterone for the Second-Line Treatment of Patients with Metastatic Hormone-Refractory Prostate Cancer (MHRPC) Progressing After the Treatment with Docetaxel: a Systematic ReviewArticleCopyright © 2014 Published by Elsevier Inc.